Effects of adequate dietary protein with whey protein, leucine, and vitamin D supplementation on sarcopenia in older adults: An open-label, parallel-group study.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Sarcopenia is defined as a syndrome characterized by declines in skeletal muscle mass and strength or an alteration in physical function.

Who Took Part

PubMed indexes the participants as older adults and people over 80, both men and women.

How the Study Was Run

In design terms this was a randomized, open-label and parallel-group study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Nothing was hidden in this open-label Vitamin D, K2, Magnesium and Zinc study: the participants and staff both knew the treatment.

Groups ran in parallel: each of the participants stayed in one arm throughout.

In total, 56 sarcopenic elders completed this study.

The appendicular muscle mass index (AMMI), handgrip strength, gait speed, and calorie and macronutrients intake were evaluated after 4 and 12 weeks of the diet intervention.

What Was Measured

PubMed files the paper under topics including Cohort Studies, Dietary Proteins, Dietary Supplements, Eating, Energy Intake, Gait and Hand Strength.

The authors tagged it with the keywords Adequate protein intake, Appendicular muscle mass index, Gait speed, Sarcopenia and Whey protein supplement.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (Clinical nutrition (Edinburgh, Scotland)), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.